
Accepted Manuscript

Title: Enigmas in tumor resistance to kinase inhibitors and calculation of the drug resistance index for cancer (DRIC)

Author: C.I. Edvard Smith



PII:	S1044-579X(16)30077-3
DOI:	http://dx.doi.org/doi:10.1016/j.semcancer.2016.11.008
Reference:	YSCBI 1278
To appear in:	Seminars in Cancer Biology
Received date:	26-8-2016
Accepted date:	9-11-2016

Please cite this article as: Smith C.I.Edvard.Enigmas in tumor resistance to kinase inhibitors and calculation of the drug resistance index for cancer (DRIC).*Seminars in Cancer Biology* http://dx.doi.org/10.1016/j.semcancer.2016.11.008

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

ACCEPTED MANUSCRIPT

Enigmas in tumor resistance to kinase inhibitors and calculation of the drug resistance index for cancer (DRIC)

C. I. Edvard Smith Clinical Research Center Dept. of laboratory medicine Karolinska Institutet Karolinska University Hospital Huddinge SE-14186 Huddinge Sweden

Correspondence:

C. I. Edvard Smith Clinical Research Center Dept. of laboratory medicine Karolinska Institutet Karolinska University Hospital Huddinge SE-14186 Huddinge Sweden

email: edvard.smith@ki.se

Keywords:

Acalabrutinib, alectinib, brigatinib, ceritinib, crizotinib, dabrafenib, dasatinib, erlotinib, gefitinib, ibrutinib, imatinib, lorlatinib, nilotinib, osimertinib, rociletinib, trametinib, vemurafenib

Download English Version:

https://daneshyari.com/en/article/8361869

Download Persian Version:

https://daneshyari.com/article/8361869

Daneshyari.com